Sign in

CIK 0001157601 · Large accelerated filer

MADRIGAL PHARMACEUTICALS, INC.

Sign in to watch
Ticker
MDGL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
(267) 824-2827
Business address
1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
Former names
MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
  1. 4 Open-market buy Director bought 91,806 shares at an average $381.49 ($35,023,032)
  2. 4 Planned sale General Counsel sold 1,077 shares at $400.00 ($430,800)
  3. 4 Planned sale President and CEO sold 11,583 shares at an average $538.65 ($6,239,198)
  4. 4 Open-market sale General Counsel sold 664 shares at $514.97 ($341,940)
  5. 4 Grant or award Director acquired 647 shares (grant or award)
  6. 3 Insider Initial Statement of Ownership
  7. 4 Open-market sale President and CEO sold 2,500 shares at an average $547.30 ($1,368,253)
  8. 4 Grant or award Director acquired 454 shares (grant or award)
  9. 4 Grant or award Director acquired 454 shares (grant or award)
  10. 4 Grant or award Director acquired 454 shares (grant or award)
  11. 4 Grant or award Director acquired 454 shares (grant or award)
  12. 4 Grant or award Director acquired 404 shares (grant or award)
  13. 4 Grant or award Director acquired 1,816 shares (grant or award)
  14. 4 Planned sale Chief Medical Officer sold 1,042 shares at $495.74 ($516,561)
  15. 4 Planned sale Director sold 5,682 shares at an average $515.44 ($2,928,716)
  16. 4 Open-market sale Chief Medical Officer sold 844 shares at $515.90 ($435,420)
  17. 4 Planned sale EVP and CFO sold 1,982 shares at an average $430.87 ($853,993)
  18. 4 Open-market sale President and CEO sold 1,663 shares at $431.94 ($718,316)
  19. 4 Open-market sale General Counsel sold 360 shares at $431.94 ($155,498)
  20. 4 Open-market sale Chief Commercial Officer sold 419 shares at $431.94 ($180,983)

Page 1 of 29 · 564 filings